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ciation for Thoracic Surgerydoi:10.1016/j.jtcvs.2004.11.001Objective: It has been postulated recently that changes in cytoskeletal and sarcolem-
mal proteins initiate a final common pathway for contractile dysfunction in dilated
cardiomyopathy. In ischemic cardiomyopathy, hepatocyte growth factor plays an
important role in reorganizing the impaired cytoskeletal proteins in several cell
types. We have tested the hypothesis that hepatocyte growth factor might improve
life expectancy through modification of the molecular process that contributes to
impairment in dilated cardiomyopathy.
Methods: Adult male 27-week-old BIO TO-2 hamsters, which show moderate
cardiac remodeling, were divided into treatment groups that received (1) hemag-
glutinating virus of Japan liposomes containing human hepatocyte growth factor
cDNA (H group), (2) culture medium (C group), or (3) sham operation (S group).
Results: After the operation, echocardiography demonstrated that the enlarged left
ventricular end-systolic dimension and decreased fractional shortening were signif-
icantly attenuated in the H group compared with the C group. There was signifi-
cantly less myocardial fibrosis in the H group compared with the C group.
Immunohistochemical analysis showed alpha-dystroglycan and alpha- and beta-
sarcoglycan expression in the basement membrane beneath the cardiomyocytes in
the H group, whereas no expression of these proteins was seen in the C group. The
40-week survival was significantly better in the H group than in the C and S groups.
Conclusion: An improved survival associated with transient reorganization of the
cytoskeletal proteins and reduction in myocardial fibrosis was achieved by hepato-
cyte growth factor treatment in an adult hamster model of dilated cardiomyopathy.
The results suggest a therapeutic potential of hepatocyte growth factor in the
treatment of dilated cardiomyopathy.
Dilated cardiomyopathy (DCM) is one of the most common causes of chronicheart failure.1 Patients have recently started to show longer survival timesbecause of improved medical therapies, such as angiotensin-converting
enzyme inhibitors and beta-blockers, and interventions, such as implantable defi-
brillators and left ventricular assist devices (LVADs).2 However, the prognosis is
still poor, and cardiac transplantation is the best treatment for DCM in advanced
cases.3,4 Unfortunately, cardiac transplantation has limitations, such as donor short-
ages, rejection, and infection.5 Therefore, novel strategies are still desired.
DCM pathology is characterized by myocardial remodeling, which is associated
with changes in the cytoskeletal and sarcolemmal proteins in cardiomyocytes,
leading to a reduction in the number and function of these cells.6 These processes
are potentially reversible, given that some patients with DCM exhibit restoration of
their cytoskeletal proteins after LVAD-mediated unloading support, which is asso-
ciated with sufficient recovery of the myocardium to allow LVAD removal.7-9
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moval may reflect a combination of abnormalities, we spec-
ulated that a good therapeutic strategy for DCM would be to
restore the disrupted cytoskeletal and sarcolemmal proteins.
Hepatocyte growth factor (HGF) is a multipotent growth
factor with antifibrotic and angiogenic effects, and it acti-
vates the matrix degradation pathway.10,11 In particular,
Taniyama and colleagues12 showed that transfection with
the HGF gene by echocardiography-guided direct injection
attenuates the progression of DCM in a hamster model.
However, this preliminary study had limitations, in that the
precise mechanism of the HGF effect and its impact on the
prognosis were still unknown. A recent report showed that
in a myocardial infarction model, HGF induced an appro-
priate microenvironment for extracellular matrix (ECM)
remodeling, including the strong expression of cytoskeletal
proteins such as alpha- and beta-dystroglycan.13 Moreover,
both these dystroglycans are major components of the dys-
trophin-associated glycoprotein complex (DGC), which
plays important roles in signal transduction and the protec-
tion of cells during heart muscle contraction.4,14 Given this
body of evidence, we hypothesized that HGF might induce
restoration of the impaired cytoskeletal proteins and mor-
phologic improvement, such as a reduction of myocardial
fibrosis, leading to an improvement in life expectancy. In
this study, we addressed the following specific questions:
(1) Can HGF induce morphologic improvement, such as
reduction of the myocardial fibrosis, and restoration of the
impaired cytoskeletal proteins in DCM? (2) Can HGF im-
prove the life expectancy for this disorder?
Methods
Experimental Animals
Male BIO TO-2 hamsters (Bio Breeders, Fitchburg, Mass), 27
weeks old, were used for this study. Humane animal care was
used, in compliance with the “Principles of Laboratory Animal
Care,” formulated by the National Society for Medical Re-
search, and “Guide for the Care and Use of Laboratory Ani-
mals,” prepared by the National Institutes of Health (Publica-
tion No. 86-23, revised 1985). The animals were divided into 3
treatment groups: The first received injections of hemaggluti-
nating virus of Japan (HVJ) liposomes containing human HGF
cDNA (H group, n  38); the second received injections of
culture medium (C group, n  29); and the third received
thoracotomy alone (S group, n  18). A total of 13 hamsters in
the H group and 10 hamsters in the C group were used for
histologic analysis at 2, 4, and 8 weeks after the operation. Six
animals in the H group and 3 in the C group were sacrificed for
measurement of human HGF concentration at 1 and 3 weeks.
The number of animals sacrificed at each time point is shown in
the figure legends. The remaining hamsters (n  19 for the H
group, n  16 for the C group, and n  18 for the S group) were
used for the evaluation of cardiac function or prognosis.
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The human HGF cDNA was inserted into the NotI site of the
pCU-SR expression vector.15 The preparation of the liposome
complex with HVJ was described previously.16 In brief, phospha-
tidylserine, phosphatidylcholine, and cholesterol were mixed. The
dried lipid was hydrated in a balanced salt solution containing
human HGF cDNA. Liposomes were prepared by shaking and
sonication of the mixture. The liposome suspension was mixed
with HVJ. Free HVJ was separated from the HVJ-liposome com-
plex by sucrose density gradient centrifugation. The top layer of
the sucrose gradient was collected for use.
Transfection of the Human HGF Gene
Hamsters were anesthetized by intraperitoneal injection of pento-
barbital (50 mg/kg body weight). The anesthetized hamsters were
intubated, and positive-pressure ventilation was maintained with a
ventilator (model SN-480-7 Shinano, Tokyo, Japan). The respira-
tory rate was set at 50 cycles/min, with a tidal volume of 2.0 mL
of room air. The heart was exposed through a 2.5-cm left lateral
thoracotomy. Approximately 0.2 mL of the HVJ-liposome-
plasmid complex (including 320 g of the human HGF cDNA)
was injected with a 30G tuberculin syringe into 1 site in the RV
and 3 sites in the LV wall (anterior free wall, apex, and posterior
wall). Control hamsters received injections of 0.2 mL of the
culture medium into the same sites as for the HGF injections. One
and 3 weeks after the transfection, the concentration of human
HGF in the cardiac tissue was measured by enzyme-linked immu-
nosorbent assay using an anti-human HGF monoclonal antibody
(Institute of Immunology, Tokyo, Japan) to document the success-
ful transfection of HGF vector into the myocardium. The antibody
against human HGF reacts only with human HGF and not with
hamster HGF.17
Measurement of Hamster Cardiac Function
Isoflurane was used for anesthesia during echocardiographic mea-
surements. The concentration of the anesthetic was reduced to 1%
and maintained for 20 minutes to stabilize the hemodynamics.
Echocardiography was performed with a commercially available
echocardiograph, SONOS 5500 (Agilent Technologies, Palo Alto,
Calif). A 12-MHz annular array transducer was used. M-mode
echocardiograms were recorded, and the left ventricular end-
systolic dimension (Ds), left ventricular end-diastolic dimension
(Dd), and fractional shortening (FS) were determined. The reader
was blinded to the study group.
Histologic Analyses
LV myocardium specimens were obtained 2, 4, and 8 weeks after
the operation. Transverse sections of the hearts (2-m thick) were
fixed with 10% buffered formalin, embedded in paraffin, and
subjected to hematoxylin and eosin (H&E) and Masson’s
trichrome staining. Frozen sections (4-m thick) were used for
immunohistochemical staining. Three-step staining was applied
for the following cytoskeletal proteins.18,19 The primary antibodies
used were anti-alpha-dystroglycan (clone: VIA4-1, Upstate Bio-
technology, Lake Placid, NY), anti-alpha-sarcoglycan, and anti-
beta-sarcoglycan (clone: Ad1/20A6 and bSarc/5B1, respectively,
Novo Castra, United Kingdom). The second antibody was biotin-
ylated rabbit antimouse antibody (K0675, DAKO, Carpinteria,
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PCalif), followed by staining with fluorescein isothiocyanate-con-
jugated streptavidin (F0422, DAKO, Carpinteria, Calif). Each pro-
tein was viewed using an ECLIPSE TE 2000-U (Nikon, Japan)
confocal microscope.
More than 5 sections were prepared for each specimen, and
every stained sample was evaluated by 2 independent pathologists
in a blinded manner. The percentage of the total area that was
fibrotic, as determined by Masson’s trichrome staining, was cal-
culated by image analysis of the sections using a planimetric
method with Windows MetaMorph software (Universal Imaging
Corporation, Downingtown, Pa). The immunohistochemical sig-
nals were quantified by the same method, and the obtained values
were expressed as a percentage of the value in F1B controls. At
least 10 low-power fields per section were analyzed by the
software.
Evaluation of Prognosis After HGF Gene Transfection
We evaluated the lifesaving effect of the HGF gene transfection on
the TO-2 hamsters, compared with culture medium injection and
sham operation. The animals were randomly allocated to each
treatment group and housed for 40 weeks after the operation. The
survivals of the animals in the H, C, and S groups were calculated
by the Kaplan-Meier method using SPSS Version 11.0 (SPSS Inc,
Chicago Ill), and the significance of the difference among the
groups at 40 weeks was tested by log-rank analyses.
Statistical Analysis
All values were expressed as the mean  SEM and subjected to
multiple analysis of variance (ANOVA) using the StatView 5.0
program (Abacus Concepts, Berkeley, Calif). Echocardiographic
data were first analyzed by 2-way repeated measurement ANOVA
for differences across the whole time course, and 1-way ANOVA
with the Tukey-Kramer post hoc test was used to verify the
significance for the specific comparison at each time point. Other
numeric data except for the survival were analyzed by 1-way
ANOVA with the Tukey-Kramer post hoc test.
Results
In Vivo HGF Gene Transfection of the Heart
We measured the human HGF concentration in the trans-
fected myocardium using an enzyme-linked immunosorbent
assay. The expression of immunoreactive human HGF was
marked in the H group myocardium, but not in that of the C
group, 1 week after the operation (Figure 1). The HGF
expression, however, was transient, given that only mar-
ginal levels of the protein were detected 3 weeks after the
transfection.
Improvement of Cardiac Function After HGF Gene
Transfection
Figure 2 shows cardiac function evaluated weekly by echo-
cardiography. The Dd, Ds, and FS at 27 weeks of age were
not significantly different between the H and C groups.
After the operation, both the Dd and Ds were gradually
enlarged and the FS was decreased in hamsters of the C
group. Although the Dd of hamsters in the H group ap-
The Journal of Thoracipeared slightly smaller than in the C group, it was also
gradually enlarged. The progressive enlargement of the Ds
observed in the C group, however, was delayed in the H
group, and hamsters in the H group showed significantly
smaller Ds and higher FS during the first 3 weeks after the
operation compared with the C group. The effect of HGF
transfection was transient, and the Ds began to increase and
the FS to decrease by 4 weeks after the transfection.
Morphologic Improvement of Cardiomyocytes After
HGF Gene Transfection
Figure 3, A illustrates typical examples of H&E and
Masson-trichrome staining in the cardiomyocytes from
F1B-strain (ie, normal) hamsters and from hamsters in the H
and C groups 4 weeks after the operation. Although H&E
staining did not show apparent differences between the H
and C groups, the Masson’s trichrome staining indicated
there was less fibrosis in the hearts of the H group. Quan-
tification of the fibrotic area confirmed this observation; the
myocardial fibrosis of hamsters in the H group was signif-
icantly suppressed compared with that in the C group (Fig-
ure 3, B).
Figure 4, A, shows representative immunohistochemical
staining results for alpha-dystroglycan and for alpha- and
beta-sarcoglycans in cardiomyocytes from F1B-strain ham-
sters. Alpha-dystroglycan and alpha- and beta-sarcoglycans
were clearly detected in the sarcolemma of the F1B ham-
sters. In contrast, the TO-2 strain, in which the promoter
Figure 1. Detection of human hepatocyte growth factor (HGF) by
enzyme-linked immunosorbent assay in transfected hearts. Hu-
man HGF protein was detected in hearts 1 week after transfection
using the hemagglutinating virus of Japan (HVJ)-liposome
method. The HGF expression, however, was transient; only mar-
ginal levels of the protein were detected 3 weeks after the
transfection. (N  3 for each group, *P < .05.)lesion of the delta-sarcoglycan gene is deleted, failed to
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and gamma-sarcoglycans.19 In addition, it was reported that
alpha-dystroglycan dissociates from beta-dystroglycan and
the other components of the dystrophin-glycoprotein com-
plex in mature cardiomyopathic hamsters.20-22 Figure 4, B
confirms these results in the TO-2 hamsters of the C group.
It is interesting that in the H-group TO-2 hamsters, alpha-
dystroglycan and alpha- and beta-sarcoglycans were readily
detected 2 weeks after the operation (Figure 4, C). However,
8 weeks after the operation, none of these proteins were
detectable in the H group (Figure 4, D).
Figure 5 shows the quantitative analysis of the immuno-
histologic signals shown in Figure 4. The area in which
there were above-background green signals in the indicated
group was compared with that of F1B hamsters, and the
relative level of expression for each protein is shown. Al-
though none of the signals for any of the 3 proteins reached
the normal levels observed in F1B hamsters 2 weeks after
the operation, the signals were significantly higher in the H
group than in the C group. Thus, weak but significant
expression of all 3 proteins was transiently observed 2
Figure 2. Cardiac performance. A and B, Left ventr
end-systolic dimension (Ds) measured by echocardiogr
and Ds. Both the Dd and Ds were gradually enlarged, a
hamsters in the H group showed a slightly smaller Dd
weeks after the operation compared with these values
and the Ds began to increase and FS began to decreas
C group (open boxes). (*P < .05 vs before operation [weeks after HGF transfection.
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Transfection
Hamsters treated with culture medium or a sham operation
(C or S group) started to die 1 week after the operation, and
the number of surviving animals decreased gradually over
the 4- to 10-week period after the operation (Figure 6).
There was no significant difference in survival between the
C and S groups (P  .8029). In contrast, almost all of the
hamsters treated with HGF gene transfection (H group)
survived for the full 40 weeks, and the H group showed
significantly better survival. The 40-week survival percent-
ages for the H, C, and S groups were 84.2%, 43.8%, and
47.9%, respectively (P  .0029 for H vs C groups, P 
.0128 for H vs S groups). Therefore, we conclude that the
life expectancy of the TO-2 hamsters was prolonged by the
HGF gene transfection.
Discussion
The present study demonstrated an improvement in the life
expectancy of adult cardiomyopathic hamsters by HGF
gene transfection. The improvement was associated with a
transient reorganization of the cytoskeletal proteins, reduc-
r end-diastolic dimension (Dd) and left ventricular
. C, Fractional shortening (FS) calculated using the Dd
was decreased in hamsters of the C group. However,
nificantly smaller Ds, and higher FS during the first 3
C group. The effect of HGF transfection was transient,
4 weeks after the transfection. H group (solid boxes);
eeks old]; #P < .05 vs C group.)icula
aphy
nd FS
, sig
in the
e by
27 wtion of myocardial fibrosis, and transient delay in the dete-
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Prioration of cardiac performance. These findings suggest
that the morphologic improvements induced by a growth
factor such as HGF may be a therapeutic strategy for tem-
porarily restoring the impaired heart in human DCM.
The TO-2 hamster strain is a representative model of
human hereditary DCM in which the promoter region of the
delta-sarcoglycan gene is deleted; this hamster fails to ex-
press alpha-, beta-, gamma-, or delta-sarcoglycan.19,23,24
Furthermore, in this hamster strain, the number of cardio-
myocytes decreases progressively after birth, and cardiac
remodeling, which mainly consists of myocardial fibrosis,
occurs with ventricular dilatation and thinning, leading to
progressive congestive heart failure; these animals start to
die when they are approximately 30 weeks old.25
HGF is a pleiotropic growth factor that shows, at least,
antifibrotic, angiogenic, and antiapoptotic effects.10,11 We
have already reported that HGF has a cardioprotective effect
because of its antiapoptotic effect on cardiomyocytes,
which is associated with a marked expression of Bcl-xL in
injured cardiomyocytes.26
In addition, Taniyama and colleagues12 reported that
HGF expression may participate in the prevention of myo-
cardial injury through antifibrotic and angiogenetic action
by up-regulation of matrix metalloproteinase (MMP)-1 in a
different hamster model of DCM. In this study, the myo-
Figure 3. Suppression of fibrotic change in the left vent
by hematoxylin-eosin (H&E) or Masson-trichrome dye.
sections stained with Masson-trichrome. The percenta
compared with that in the C group. (N  5 for each gcardial fibrosis was significantly reduced after HGF gene
The Journal of Thoracitransfection. Therefore, one explanation for the reduction of
the progressive decrease in cardiac performance in the ham-
ster model of DCM is the antifibrotic and probably anti-
apoptotic effects elicited by HGF.
Another important effect of HGF is to induce an
appropriate microenvironment for ECM remodeling, in-
cluding a strong expression of cytoskeletal proteins such
as alpha- and beta-dystroglycan.13 The DGC is composed
of dystrophin, the dystroglycans (alpha-, beta-subunits),
the sarcoglycans (alpha-, beta-, gamma-, delta-subunits),
sarcospan, the dystrobrevins, and the syntrophins.14,27
This DGC component serves as a link between the intra-
cellular cytoskeleton and the ECM. Although the precise
function of the DGC has not been elucidated, the current
main hypothesis is that it has a mechanical function to
strengthen the plasma membrane during heart muscle
contraction.4 In addition, several lines of evidence sug-
gest another important role for the DGC in signal trans-
duction pathways, which it appears to share with the
syntrophins and/or calmodulin.14
In this study, immunohistochemical staining demon-
strated the expression of alpha- and beta-sarcoglycans in the
H group, whereas there was no expression of these proteins
in the C group, although the mechanism of the reconstitu-
tion of these proteins by HGF is unknown. Concomitant loss
of TO-2 hamsters by HGF. Tissue sections were stained
brous area was quantified by image analysis in tissue
f fibrosis in the H group was significantly suppressed
*P < .05.)ricle
The fi
ge o
roup,of all the sarcoglycans causes the contraction-induced dam-
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even in small amounts, prevents this damage in a mouse
model.28 Taking all this information together, we speculate
that the transient expression of the alpha- and beta-sarco-
glycans induced by HGF may be associated with reduction
of the myocardial damage and that such a reduced damage
may contribute to the subsequent attenuation of myocardial
fibrosis and/or the delay in deterioration of cardiac
performance.
In addition, immunohistochemical staining of cardiomyo-
cytes demonstrated the re-expression of alpha-dystroglycan in
group H. Yamada and colleagues29 suggested 2 possible mech-
anisms for the dissociation of alpha-dystroglycan from beta-
dystroglycan in sarcoglycanopathy, which is characterized by a
deficiency of the sarcoglycan complex because of primary
defects in the genes for these proteins. One mechanism is that
MMPs, which degradate ECM activity, might be responsible
for processing beta-dystroglycan, and the other mechanism is
that the sarcoglycan complex might mask the MMP cleavage
site on beta-dystroglycan in normal muscle.29 But the defi-
Figure 4. Immunostaining for alpha-dystroglycan and
hamster, 27 weeks old; B, C-group hamster 2 weeks
operation; D, H-group hamster, 8 weeks after the operat
were clearly detected in the sarcolemma of the F1B st
sarcoglycans was detected (B). In contrast, in the H
alpha- and beta-sarcoglycans 2 weeks after the transfe
the transfection (D).ciency of the sarcoglycan complex in sarcoglycanopathy ex-
300 The Journal of Thoracic and Cardiovascular Surgery ● Auguposes the cleavage site and induces the MMPs processing of
beta-dystroglycan.29 From these reports we speculate that the
reconstitution of alpha-dystroglycan into the membrane frac-
tion may occur because the sarcoglycans expressed after trans-
fection with the HGF gene may mask the MMP cleavage site
on beta-dystroglycan and/or MMP activity may be inhibited by
HGF.
Moreover, alpha-dystroglycan is connected to laminin
extracellularly. Cell-matrix interactions mediated by lami-
nin and integrin elicit various cell functions, such as prolif-
eration, differentiation, motility, and protein production.23
HGF is known to modulate the laminin/integrin interactions
to enhance cell– cell and cell–ECM interactions.23 Although
we did not immunolabel integrin and laminin in this study,
laminin activity enhanced by HGF may have played an
important role in the histologic and functional recovery of
cardiomyocytes in the TO-2 hamsters.
We showed that the life expectancy of the TO-2 hamsters
was prolonged by transfection with the HGF gene. Several
reports have shown that the life expectancy of TO-2 hamsters
a- and beta-sarcoglycans in cardiomyocytes. A, FIB
the operation; C, H-group hamster 2 weeks after the
lpha-dystroglycan, and alpha- and beta- sarcoglycans
hamsters (A). In the C group, neither dystroglycan nor
, cardiomyocytes expressed alpha-dystroglycan, and
(C), but this expression disappeared by 8 weeks afteralph
after
ion. A
rain
group
ctionis significantly prolonged by delta-sarcoglycan gene transfec-
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Ption and oral therapy with the angiotensin-converting enzyme
inhibitor enalapril.25,30 In these reports, the treatments were
started at 5 and 6 weeks of age, respectively, before cardiac
function was impaired. Here, the HGF treatment was given
Figure 5. Quantitative results of the immunohistologic signals
shown in Figure 4. A, Alpha-dystroglycan. B, Alpha-sarcoglycan.
C, Beta-sarcoglycan. Although the signals for all 3 proteins had
not reached the normal levels observed in F1B mice 2 weeks after
the operation, they were significantly higher in the H group than
in the C group. (H-2w, 2 weeks after the operation in the H group;
H-8w, 8 weeks after the operation in the H group; C-2w, 2 weeks
after the operation in the C group; N  5 for H-2w and C-2w, N 
3 for H-8w, *P < .05.)
Figure 6. Survivals. The percentage of surviving animals at 40
weeks was 84.2% for the H group, 43.8% for the C group, and
47.9% for the S group. There was no significant difference be-
tween the C and S groups, but there was a significant difference
between the H and C groups. (H group, N  19; C group, N  16;
S group, N  18.)when the hamsters were 27 weeks old. It is very interesting that
The Journal of Thoracieven at such a late phase of DCM, transfection with the HGF
gene induced the reorganization of the cytoskeletal proteins,
leading to an improvement in the cardiac performance of the
impaired heart.
The disadvantage of using the HVJ-liposome method to
transfect HGF is that the secretion of HGF is sustained for
only a few weeks after the transfection; we believe that the
loss of HGF expression explains the gradual decrease in
cardiac function we observed, which started 4 weeks after
the surgery. Therefore, longer-term HGF secretion methods
must be considered to maintain the cardiac function, such as
the repeated administration of HGF or a slow-release deliv-
ery system. Further investigation is needed to determine the
best approach for clinical applications.
In summary, transfection with the HGF gene induced
transient morphologic improvement, including the reduc-
tion of myocardial fibrosis and reorganization of the cy-
toskeletal proteins in a hamster model of DCM; these
changes led to a delay in the deterioration of cardiac per-
formance and an improvement in life expectancy.
We thank Akiko Nishimura, Masako Yokoyama, and Aiko
Miki for their excellent technical assistance.
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